Narasimha Boorgu, MD
Nephrology · Florence, ALNPI 1043218928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 574 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations.
Across 574 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$1K
- OPKO Pharmaceuticals, LLC$1K
- Amgen$914
- Otsuka America Pharmaceutical, Inc.$754
- AstraZeneca$708
- Akebia Therapeutics Inc$703
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,28897%
- Education$2863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 76 | $1,120 |
| OPKO Pharmaceuticals, LLC | 112 | $1,045 |
| Amgen(2 entities) | 54 | $914 |
| Otsuka America Pharmaceutical, Inc. | 42 | $754 |
| AstraZeneca(2 entities) | 38 | $708 |
| Akebia Therapeutics Inc | 35 | $703 |
| Bayer | 28 | $540 |
| Calliditas Therapeutics US Inc. | 21 | $447 |
| Novartis | 15 | $392 |
| Novo Nordisk | 23 | $382 |
| Boehringer Ingelheim | 16 | $322 |
| Lilly USA, LLC | 16 | $289 |
| GSK | 14 | $246 |
| Mallinckrodt Hospital Products Inc. | 10 | $231 |
| Sanofi-aventis U.S. LLC | 12 | $178 |
| Mallinckrodt Enterprises LLC | 6 | $169 |
| Fresenius USA Marketing, Inc. | 8 | $158 |
| Ardelyx, Inc. | 9 | $151 |
| Corcept Therapeutics | 6 | $124 |
| Travere Therapeutics, Inc. | 5 | $118 |
| Aurinia Pharma U.S., Inc. | 4 | $105 |
| Abbott | 4 | $73 |
| Bard Peripheral Vascular, Inc. | 2 | $56 |
| Shield Therapeutics Inc | 2 | $41 |
| Shire North American Group Inc | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Insulet Corporation | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Vantive US Healthcare LLC | 1 | $25 |
| BETA Bionics, Inc. | 1 | $24 |
| Nuwellis, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$105
How this compares
$9,574 in reported general payments places this provider in the 80th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 325 | $377,863 |
| MounjaroTirzepatide | 315 | $376,700 |
| KerendiaFinerenone | 178 | $162,134 |
| FarxigaDapagliflozin Propanediol | 162 | $140,571 |
| Repatha SureclickEvolocumab | 181 | $130,236 |
| TrulicityDulaglutide | 76 | $91,802 |
| JardianceEmpagliflozin | 87 | $85,273 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $48,575 |
| XphozahTenapanor Hcl | 15 | $46,103 |
| VeltassaPatiromer Calcium Sorbitex | 29 | $40,938 |
| VelphoroSucroferric Oxyhydroxide | 12 | $37,729 |
| EliquisApixaban | 39 | $35,255 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $29,468 |
| RayaldeeCalcifediol | 21 | $27,076 |
| WegovySemaglutide | 13 | $27,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $289 | $468,502391 claims |
| Novo NordiskOzempic, Wegovy | $382 | $404,939338 claims |
| AstraZenecaFarxiga, Lokelma | $708 | $189,146210 claims |
| BayerKerendia | $540 | $162,134178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $322 | $96,63798 claims |
| Fresenius USA Marketing, Inc.Velphoro | $158 | $37,72912 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,045 | $27,07621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 nephrology providers in Alabama.
Other nephrology in Florence
- Subir PaulFlorence$26K
- Dwight MatthewFlorence$4K
- Rajesh BoorguFlorence$4K
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.